scholarly journals Quasi-Complete Response of Classic Kaposi’s Sarcoma Treated with Weekly Paclitaxel

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Zineb Benbrahim ◽  
Samia Arifi ◽  
Hafida Benhammane ◽  
Kaoutar Inani ◽  
Salim Gallouj ◽  
...  
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Skin Lesions ◽  
Weekly Paclitaxel ◽  
Classical Type ◽  
Prior Therapy ◽  
Visceral Involvement ◽  
First Line Therapy ◽  
Late Stages

Classic Kaposi’s sarcoma (CKS) is a subtype that traditionally occurs in elderly HIV-negative males of Mediterranean origin. Patients with CKS characteristically present with skin lesions in the distal extremities. Involvement of the viscera is uncommon but may occur in the late stages of the disease. Patients with extensive KS can be treated with systemic chemotherapy. A number of drugs approved for treatment of AIDS-associated KS, especially Paclitaxel, have activity against CKS after failure of prior therapy. We report a patient treated with weekly Paclitaxel, as initial chemotherapy, for CKS presenting with multiple visceral involvement and having a contraindication for Bleomycin. The patient had quasi-complete response after three months of chemotherapy suggesting that weekly Paclitaxel might be effective as a first-line therapy for classical type KS with visceral involvement.

Electrochemotherapy In The Treatment of Kaposi’s Sarcoma: A Single Centre Cohort Study And A Comparison With Literature Data

2021 ◽  
Vol 01 ◽  
Author(s):  
Edoardo Cammarata ◽  
Roberto Giorgione ◽  
Marco Andreassi ◽  
Chiara Airoldi ◽  
Paola Savoia
Keyword(s):  
Kaposi's Sarcoma ◽  
Human Herpesvirus ◽  
Kaposi’S Sarcoma ◽  
Surgical Excision ◽  
Complete Response ◽  
Skin Lesions ◽  
Cytotoxic Agents ◽  
Electric Pulses ◽  
Local Toxicity ◽  
Reversible Electroporation

: Kaposi's sarcoma (KS) is a tumor of endothelial derivation, which primarily affects the skin and is mainly related to the type 8 human herpesvirus (HHV8). Its onset is favored by immunosuppression, although the most common form is the classic or sporadic KS mainly developing in elderly men of Mediterranean and Eastern European origin. Different therapeutic options are available, depending on the clinical variant, progression pattern, and comorbidities. The treatment of localized forms includes surgical excision, laser treatment, cryosurgery, radiotherapy, imiquimod 5%, and intra-lesion injection of cytotoxic drugs; on the other hand, the treatment of widespread disease encompasses radiotherapy and chemotherapy. In this scenario, electrochemotherapy (ECT), has shown to be an effective alternative to traditional treatment for disseminated KS skin lesions. The rationale of ECT relies on the local application of short, high-voltage electric pulses, able to open transient pores in the cell membrane (reversible electroporation, that increases the delivery of some poorly permeant cytotoxic agents into the cytosol. Herein we performed a retrospective analysis on 9 KS patients treated with ECT at our center between June 2016 and January 2020. The rate of Complete Response (CR) was 77.8% after the first cycle of treatment and 88.9% after the second course, with an overall response (OR) of 100%. Sustained local control of treated lesions was present in 77.8% of patients 6 months after the treatment and all of them reported only mild local toxicity, together with an excellent functional and cosmetic outcome, in agreement with data obtained from the comparison with the recent literature.

scholarly journals Primary Gastrointestinal Kaposi’s Sarcoma in a Patient with Human Immunodeficiency Virus

2018 ◽  
Vol 11 (3) ◽  
pp. 638-647 ◽  
Author(s):  
Martin Ignacio Zapata Laguado ◽  
Jorge Enrique Aponte Monsalve ◽  
Jorge Hernan Santos ◽  
Javier Preciado ◽  
Andres Mosquera Zamudio ◽  
...  
Keyword(s):  
Gastrointestinal Bleeding ◽  
Kaposi's Sarcoma ◽  
Gastrointestinal Endoscopy ◽  
Rare Complication ◽  
Kaposi’S Sarcoma ◽  
Skin Lesions ◽  
Clinical Findings ◽  
Upper Gastrointestinal Endoscopy ◽  
Immunodeficiency Virus ◽  
Upper Gastrointestinal

Gastrointestinal bleeding in HIV patients secondary to coinfection by HHV8 and development of Kaposi’s sarcoma (KS) is a rare complication even if no skin lesions are detected on physical examination. This article indicates which patients might develop this type of clinical sign and also tries to recall that absence of skin lesions never rules out the presence of KS, especially if gastrointestinal involvement is documented. Gastrointestinal bleeding in terms of hematemesis has rarely been reported in the literature. We review some important clinical findings, diagnosis, and treatment approach. We present the case of an HIV patient who presented to the emergency department with hematemesis and gastrointestinal signs of KS on upper gastrointestinal endoscopy without any dermatological involvement.

scholarly journals Therapeutic Outcomes in AIDS-Associated Kaposi's Sarcoma Patients on Antiretroviral Therapy Treated with Chemotherapy at Two Tertiary Hospitals in Lusaka, Zambia

2018 ◽  
Vol 16 (3) ◽  
pp. 231-236 ◽  
Author(s):  
Watson Mtonga ◽  
Aaron Mujajati ◽  
Derick Munkombwe ◽  
Aubrey Kalungia ◽  
Lungwani Tyson Muungo ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
University Teaching ◽  
Teaching Hospitals ◽  
Recurrence Rates ◽  
Therapeutic Outcomes ◽  
Efficacious Treatment ◽  
Study Participants

The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47%) after 6 cycles of ABV whereas 20 (53%) experienced a partial response. KS recurrence was observed in 8 (44%) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55%) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.

scholarly journals Kaposi’s sarcoma in Brazilian AIDS patients: a study of 144 cases

2000 ◽  
Vol 14 (4) ◽  
pp. 362-366 ◽  
Author(s):  
Esther G. BIRMAN ◽  
Fernando R. X. SILVEIRA ◽  
Luzia F. GODOY ◽  
Catalina R. COSTA
Keyword(s):  
Oral Mucosa ◽  
Kaposi's Sarcoma ◽  
Young Male ◽  
Kaposi’S Sarcoma ◽  
Skin Lesions ◽  
Bacterial Disease ◽  
Aids Patients ◽  
Main Site ◽  
Oral Neoplasms ◽  
Age Range

One hundred and forty-four Brazilian AIDS patients presenting with Kaposi’s sarcoma (KS) were evaluated with respect to the frequency of oral neoplasms and their clinical features. The majority of the patients were young male adults (age range: 21-40 years old), from which 11.1 % presented with oral KS (OKS) exclusively. Oral and skin lesions were associated in 25% of the cases, while only four patients showed association between oral and visceral KS; 49.3% of the cases were exclusively dermatological. The hard palate was the main site affected, followed by the oropharynx. The localization of KS was found to be similarly frequent in the tongue, gingiva and other sites of the oral mucosa. Candidosis was the prevailing fungal disease; in 20% of the cases it was restricted to the oral mucosa and in 80% it was systemic. No high frequency of paracoccidioidomicosis and cryptococcosis was detected. The prevailing bacterial disease was Tuberculosis and there was only one case of syphilis. Among the viral diseases, the most frequently detected was herpes simplex, followed by molusco contagiosum, condiloma acuminatum and cytomegaloviroses at lower frequencies. Pneumonia caused by Pneumocystes carinii and toxoplasmosis were also identified. The authors emphasise the importance of oral examination in HIV-infected patients bearing in mind several aspects related especially to KS, and stress the need for an interdisciplinary team in the management of these patients, in order to provide better quality of life as well as rapid diagnosis and treatment.

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

1998 ◽  
Vol 16 (3) ◽  
pp. 1112-1121 ◽  
Author(s):  
L Welles ◽  
M W Saville ◽  
J Lietzau ◽  
J M Pluda ◽  
K M Wyvill ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Kaposi's Sarcoma ◽  
Single Agent ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Pulmonary Involvement ◽  
Dose Titration ◽  
Treatment Schedule ◽  
Creatinine Concentration ◽  
Immunodeficiency Virus

PURPOSE To investigate the antitumor activity and safety of paclitaxel in patients with advanced human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS). PATIENTS AND METHODS Twenty-nine patients with advanced HIV-associated KS were enrolled. The patients were overall quite immunosuppressed (median CD4 count, 15 cells/microL). Paclitaxel was initially administered at 135 mg/m2 over 3 hours every 3 weeks without filgrastim support; the dose was increased as tolerated to a maximum of 175 mg/m2. Patients who failed to respond or progressed could then receive filgrastim support or paclitaxel administered over 96 hours. RESULTS Of 28 assessable patients, 20 had major responses (18 partial responses [PRs], one clinical complete response [CR], and one CR), for a major response rate of 71.4% (95% confidence interval [CI], 51.3% to 86.8%). Each of the five patients with pulmonary KS responded, as did all four assessable patients who had previously received anthracycline therapy for KS. Of six patients who went on to receive a 96-hour infusion of paclitaxel, five had major responses. Neutropenia was the most frequent dose-limiting toxicity; possible novel toxicities included late fevers, late rash, and eosinophilia. Two patients developed an elevated creatinine concentration and one cardiomyopathy. CONCLUSION Paclitaxel has substantial activity against advanced HIV-associated KS as a single agent, even in patients with pulmonary involvement or who had previously received anthracyclines. Further research is needed to define the optimal treatment schedule and its role vis-a-vis the other available therapies for this disease.

Sign in / Sign up

Export Citation Format

Share Document